ALIMTA (Pemetrexed) in Patients With Locally Advanced or Metastatic Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This is a non-randomized, phase 1, study with the primary objective of determining the
toxicities and establishing the maximum tolerated dose of ALIMTA when administered as a 10
minute infusion every 21 days with folic acid or multi-vitamin supplementation therapy in
lightly or heavily pre-treated patients with locally advanced or metastatic cancer.